Weifa ASA : Information regarding the contemplated Offering in Vistin Pharma ASA

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES

Oslo, Norway, 15 May 2015

Weifa ASA (OSE: WEIFA), reference is made to Weifa ASA's ("Weifa") announcement on 20 April 2015 regarding the contemplated sale of Weifa's B2B business and tablet production to the newly established company Vistin Pharma AS, and the contemplated equity issue (the "Offering") in Vistin Pharma ASA (the "Company" or "Vistin Pharma").

The Offering consists of two tranches;

• 15,554,935 new shares at NOK 10 per new share (the "New Shares") are directed towards the shareholders of Weifa as of 19 May 2015 (the "Rights Offering"), who are not resident in a jurisdiction where such offering would be unlawful or would (in jurisdictions other than Norway) require any prospectus filing, registration or similar action (the "Eligible Shareholders"); and
• 1,500,000 new shares at NOK 10 per new share (the "Employee Offer Shares") are directed towards the Company's employees, executive management and Board of Directors (the "Employee Offering").

The last day of trading in the Weifa share including the right to receive subscription rights in Vistin Pharma will be 19 May 2015. Each eligible shareholder will be granted one subscription right for every 102 Weifa shares owned as of 19 May 2015, as registered in the shareholder register in the VPS as of the end of 21 May 2015. One subscription right will, subject to applicable securities law, give the holder the right to subscribe for and be allocated one (1) new share in the Company in the Rights Offering. Oversubscription is allowed. Subscription without subscription rights is not permitted.

The Weifa share will trade exclusive the right to receive subscription rights from and including 20 May 2015.

The subscription period in the Offering is expected to commence on 26 May 2015 at 09:00 CET and expire on 4 June 2015 at 16:30 CET. The trading period for the subscription rights is expected to commence on 26 May 2015 at 09:00 and expire on 2 June 2015 at 16:30 CET. All dates are subject to the approval of the prospectus. Oslo Børs' resolution on whether to accept the Company's application for listing of its shares on Oslo Axess is expected to be announced on 26 May 2015.

The allocation of shares is expected to take place on or about 5 June 2015 and the listing and first day of trading of Vistin Pharma's shares on Oslo Axess is expected to commence on or about 10 June 2015 (subject to approval of the Company's listing application by the board of directors on the Oslo Stock Exchange and the fulfilment of certain listing requirements).  

Further information regarding the terms of the Offering will be published upon approval of the Vistin Pharma prospectus.

Contact:

Kjell-Erik Nordby
CEO
+47 913 64 280
Kjell-erik.nordby@weifa.no

Gunnar Manum
CFO
+47 951 79 190
gunnar.manum@weifa.no

* * *